Colorectal Cancer
Conditions
Interventions
Case series:raltitrexed plus Irinotecan
Sponsors
81th Hospital of PLA, Dongfang Hospital Affiliated to Shanghai Tongji University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Above 18 years old male or female; 2. histological and/or cytological confirmation of ACC; 3. Disease progression while on first-line palliative fluoropyrimidine-based chemotherapy or relapse within 6 months after adjuvant chemotherapy or first-line maintenance treatment within 3 months of disease progression; and from the last chemotherapy for more than one month; 4. at least one measurable objective tumor lesion by spiral CT examination, the maximum diameter = 1cm(according to RECIST 1.1); 5. Participants volunteered to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. History of malignancy within 5 years except treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma; 2. inflammatory bowel disease or a history of extensive removal of the colon> 50% or extensive small bowel resection with chronic diarrhea; 3. uncontrolled brain metastasis; 4. uncontrolled ascites with clinical intervention; 5. pregnant or lactated women; 6. unsuitable for the study determined by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Objective Response Rate;Disease Control Rate;Percentage of participants experiencing grade 3-4 adverse events;Quality of Life; | — |
Countries
China
Contacts
Public ContactQin Shukui, Li Jin
81th Hospital of PLA / Oriental Hospital, Shanghai Tonji University
Outcome results
None listed